TuHURA Biosciences (HURA) Cash from Financing Activities (2011 - 2026)

TuHURA Biosciences' Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 1403.21% year-over-year to $7.1 million in Q1 2026; TTM through Mar 2026 was $27.6 million, a 54.65% decrease from a year earlier, with the FY2025 full-year figure at $19.9 million, down 33.07% from the prior year.
• Cash from Financing Activities rose to $7.1 million in Q1 2026 per HURA's latest filing, from $6.5 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $33.3 million in Q3 2024 and bottomed at -$11.8 million in Q2 2023.
• The 5-year median for Cash from Financing Activities is $1.9 million (2022), against an average of $5.4 million.
• Across the five-year window, Cash from Financing Activities jumped 1664519.0% in 2024 and plunged 105.18% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $1.9 million in 2022, then tumbled by 56.61% to $806249.0 in 2023, then jumped by 4028.8% to $33.3 million in 2024, then slumped by 80.45% to $6.5 million in 2025, then rose by 9.74% to $7.1 million in 2026.
• Per Business Quant, the three latest HURA Cash from Financing Activities figures stand at $7.1 million (Q1 2026), $6.5 million (Q4 2025), and $5.3 million (Q3 2025).